Evaluation of clinical efficacy and therapeutic effect of fostatinib (fotantinib)

Fostamatinib (also known as Fostamatinib) is an oral spleen tyrosine kinase (Syk) inhibitor. It is mainly used to treat chronic immune thrombocytopenia (ITP). It is especially suitable for refractory adult patients who are refractory to first-line treatments such as corticosteroids and immunoglobulins. It effectively reduces immune-mediated platelet destruction by regulating the abnormal activation mechanism of the immune system, thereby increasing platelet count.

In clinical studies, fostatinib has shown a clear therapeutic effect. According to relevant III phase clinical trial data, approximately 18% to 25% of ITP patients can survive 50×10⁹/L) is achieved within an>24weeks, and some patients can even achieve a significant increase in platelet levels in a shorter period of time. This has important clinical implications for patients with recurrent bleeding or who are resistant to other treatments.

In addition toITP, fostatinib has also been studied for the treatment of immune-related diseases such as rheumatic diseases and autoimmune hemolytic anemia, showing good potential application prospects. Because its mechanism of action targets immune-mediated inflammation and cell destruction pathways, it can achieve disease control effects in some immune diseases, and it has strong targeting and relatively reduces damage to normal cells.

Although the efficacy of fostatinib is clear, some patients may experience adverse reactions such as hypertension, diarrhea, and elevated liver enzymes during treatment. Therefore, liver function, blood pressure, and blood routine indicators need to be regularly monitored during use. Overall, fostatinib provides a new treatment path for patients with refractory ITP. Its stable increase in platelet capacity and good tolerability make it an important choice for second-line treatment.

Reference materials:https://www.drugs.com/